[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Hoshi A, Tokunaga M, Usui Y, Yamashita H, Sasaki H, Kobayashi Y, Shima M, Miyakita H, Terachi T: [Metastatic small intestinal tumor associated with transitional cell carcinoma: a report of 2 cases and review of cases in Japan]. Hinyokika Kiyo; 2005 Jan;51(1):41-4
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic small intestinal tumor associated with transitional cell carcinoma: a report of 2 cases and review of cases in Japan].
  • Transitional cell carcinoma (TCC) frequently metastasizes to lymph nodes, liver, lungs and bone.
  • Case 1: A 87-year-old man had a history of bladder tumor (TCC, grade 3, pT2bN0M0) and has transurethral resection of bladder tumor (TUR-BT) three times.
  • As computed tomography (CT) showed abdominal free air, our diagnosis was perforation of gastrointestinal tract.
  • We found the elastic hard tumor in the ileum on the perforated lesion, which showed metastatic TCC in the ileum pathologicaly.
  • CT showed a bladder tumor invaded into the prostate (pT4aN1M0), we performed total cyctectomy and ileal conduit after neo-adjuvant chemotherapy.
  • During the operation, we found the tumor (2 cm in diameter) in the small intestine which was metastasized of bladder tumor.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Ileal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732341.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 15
  •  go-up   go-down


2. Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil MK, Rodrigue-Gervais IG, Gaboury L, Lamarre D, Basik M, Meloche S: Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer; 2008;8:337
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
  • BACKGROUND: The Ras-dependent ERK1/2 MAP kinase signaling pathway plays a central role in cell proliferation control and is frequently activated in human colorectal cancer.
  • Small-molecule inhibitors of MEK1/MEK2 are therefore viewed as attractive drug candidates for the targeted therapy of this malignancy.
  • However, the exact contribution of MEK1 and MEK2 to the pathogenesis of colorectal cancer remains to be established.
  • METHODS: Wild type and constitutively active forms of MEK1 and MEK2 were ectopically expressed by retroviral gene transfer in the normal intestinal epithelial cell line IEC-6.
  • RNA interference was used to test the requirement for MEK1 and MEK2 function in maintaining the proliferation of human colorectal cancer cells.
  • RESULTS: We found that expression of activated MEK1 or MEK2 is sufficient to morphologically transform intestinal epithelial cells, dysregulate cell proliferation and induce the formation of high-grade adenocarcinomas after orthotopic transplantation in mice.
  • A large proportion of these intestinal tumors metastasize to the liver and lung.
  • Importantly, we show that silencing of MEK2 expression completely suppresses the proliferation of human colon carcinoma cell lines, whereas inactivation of MEK1 has a much weaker effect.
  • CONCLUSION: MEK1 and MEK2 isoforms have similar transforming properties and are able to induce the formation of metastatic intestinal tumors in mice.
  • Our results suggest that MEK2 plays a more important role than MEK1 in sustaining the proliferation of human colorectal cancer cells.
  • [MeSH-major] Adenocarcinoma / secondary. Cell Transformation, Neoplastic. Intestinal Mucosa / pathology. Intestinal Neoplasms / pathology. MAP Kinase Kinase 1 / metabolism. MAP Kinase Kinase 2 / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 May 14;26(22):3227-39 [17496918.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Int J Exp Pathol. 2008 Feb;89(1):1-12 [18081801.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):543-56 [10662779.001]
  • [Cites] Oncogene. 2000 Mar 23;19(13):1665-75 [10763823.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2686-92 [11031257.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):233-6 [12086859.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6023-33 [12167697.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4781-90 [12183438.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] Int J Oncol. 2003 Mar;22(3):469-80 [12579299.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8118-25 [12506122.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):395-403 [12884914.001]
  • [Cites] Nat Cell Biol. 2003 Aug;5(8):733-40 [12844146.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Aug;4(8):657-65 [12923528.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5669-73 [14522881.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6785-93 [14555991.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42615-24 [12915405.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):763-76 [14737111.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 May;286(5):G736-46 [14701721.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 May;5(5):355-66 [15122349.001]
  • [Cites] J Invest Dermatol. 2004 Sep;123(3):503-15 [15304090.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6035-40 [15342384.001]
  • [Cites] J Natl Cancer Inst. 1974 Sep;53(3):661-74 [4412247.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4562-9 [1000501.001]
  • [Cites] J Natl Cancer Inst. 1977 Jul;59(1):221-6 [327080.001]
  • [Cites] J Cell Biol. 1979 Feb;80(2):248-65 [88453.001]
  • [Cites] Br J Cancer. 1983 Mar;47(3):373-81 [6830688.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6863-71 [2846163.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cell. 1994 Jun 17;77(6):841-52 [7911739.001]
  • [Cites] Science. 1994 Aug 12;265(5174):966-70 [8052857.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686-9 [7644477.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3265-71 [8621729.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):6924-8 [8692920.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11426-33 [9111053.001]
  • [Cites] Mol Endocrinol. 1997 Oct;11(11):1618-25 [9328344.001]
  • [Cites] Gastroenterology. 1997 Nov;113(5):1589-98 [9352861.001]
  • [Cites] J Cell Physiol. 1998 Jan;174(1):35-47 [9397154.001]
  • [Cites] Curr Opin Oncol. 1999 Jan;11(1):68-75 [9914881.001]
  • [Cites] Nucleic Acids Res. 1999 May 15;27(10):2086-90 [10219080.001]
  • [Cites] Cell Growth Differ. 1999 May;10(5):317-32 [10359013.001]
  • [Cites] Nat Med. 1999 Jul;5(7):810-6 [10395327.001]
  • [Cites] Virology. 1964 Jun;23:291-4 [14187925.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):298-306 [15549091.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):937-47 [15573115.001]
  • [Cites] J Cell Biol. 2005 Jan 3;168(1):55-66 [15631990.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):322-7 [15863380.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):577-90 [16083714.001]
  • [Cites] Front Biosci. 2006;11:479-91 [16146745.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):103-14 [16098678.001]
  • [Cites] Mol Cancer. 2006;5:63 [17112382.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2040-8 [18003960.001]
  • (PMID = 19014680.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; EC 2.7.1.- / MAP2K1 protein, human; EC 2.7.1.- / MAP2K2 protein, human; EC 2.7.12.2 / MAP Kinase Kinase 1; EC 2.7.12.2 / MAP Kinase Kinase 2; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2596176
  •  go-up   go-down


3. Sano F, Kimura R, Fujikawa N, Sugiura S, Hirai K, Ueki T, Kitami K: Muscle and small intestinal metastasis of renal cell carcinoma markedly responsive to interferon-alpha therapy: a case report. Hinyokika Kiyo; 2007 Sep;53(9):635-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle and small intestinal metastasis of renal cell carcinoma markedly responsive to interferon-alpha therapy: a case report.
  • Skeletal muscle and small intestine are rare sites of metastasis in renal cell carcinoma.
  • Therefore very few reports of interferon-alpha (IFN-alpha) therapy exist for these types of metastasis.
  • Here, a case of metastatic renal cell carcinoma to muscle and jejunum is reported.
  • After IFN-alpha therapy for 9 weeks, muscle metastasis completely disappeared and intestinal lesions were markedly reduced.
  • However, subsequent patient compliance for this therapy was poor, resulting in death after relapse of the RCC.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / pathology. Interferon-alpha / therapeutic use. Jejunal Neoplasms / secondary. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Muscle Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933140.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


Advertisement
4. Hata K, Kitayama J, Shinozaki M, Komuro Y, Watanabe T, Takano T, Iwase S, Nagawa H: Intestinal perforation due to metastasis of breast carcinoma, with special reference to chemotherapy: a case report. Jpn J Clin Oncol; 2001 Apr;31(4):162-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal perforation due to metastasis of breast carcinoma, with special reference to chemotherapy: a case report.
  • We report a case of small-bowel perforation due to metastatic carcinoma of the breast during chemotherapy.
  • Partial resection of the small intestine and primary anastomosis were performed.
  • Since perforation during chemotherapy results in an extremely poor prognosis, special caution during chemotherapy is needed for patients with possible gastrointestinal involvement with tumor.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma, Scirrhous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Intestinal Neoplasms / secondary. Intestinal Perforation / etiology. Intestine, Small. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11386463.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Poncet G, Faucheron JL, Walter T: Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol; 2010 Apr 14;16(14):1696-706

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.
  • Well-differentiated endocrine carcinomas of the small bowel are fairly rare neoplasms that present many clinical challenges.
  • Initial treatment aims to control carcinoid syndrome with somatostatin analogs.
  • Even if there is metastatic spread, surgical resection of the primitive tumor should be discussed in cases of retractile mesenteritis, small bowel ischemia or subocclusive syndrome in order to avoid any acute complication, in particular at the beginning of somatostatin analog treatment.
  • The choice of treatment depends on the symptoms, general health of the patient, tumor burden, degree of uptake of radionuclide, histological features of the tumor, and tumor growth.
  • Management strategies include surgery for cure (which is rarely achieved) or for cytoreduction, radiological interventions (transarterial embolization or radiofrequency ablation), and chemotherapy (interferon and somatostatin analogs).
  • New biological agent and radionuclide targeted therapies are under investigation.
  • Finally, it has to be emphasized that it is of the utmost importance to enroll these patients with a rare disease in prospective clinical trials assessing new therapeutic strategies.
  • [MeSH-major] Intestinal Neoplasms / therapy. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Algorithms. Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Humans. Intestine, Small. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endocrinol Invest. 2003;26(8 Suppl):14-6 [15233205.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:67-73 [15477721.001]
  • [Cites] N Engl J Med. 1967 Nov 23;277(21):1103-8 [6054996.001]
  • [Cites] Cancer Clin Trials. 1979 Winter;2(4):327-34 [93982.001]
  • [Cites] N Engl J Med. 1983 Jul 21;309(3):129-33 [6191217.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1255-9 [6238136.001]
  • [Cites] Am J Med. 1986 Dec 22;81(6B):41-8 [2432780.001]
  • [Cites] Am J Med. 1987 May 29;82(5B):77-83 [3035924.001]
  • [Cites] Anaesthesia. 1987 Jun;42(6):627-32 [2887127.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):2891-5 [2960446.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):377-83; discussion 384-5 [2368441.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2624-30 [8384072.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):244-8 [8389666.001]
  • [Cites] Endocr Relat Cancer. 2008 Dec;15(4):1083-97 [18603570.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):338-45 [19118063.001]
  • [Cites] Neuroendocrinology. 2009;89(3):308-14 [19307732.001]
  • [Cites] Digestion. 2009;79(3):137-42 [19307736.001]
  • [Cites] Rev Endocr Metab Disord. 2009 Jun;10(2):91-102 [18642088.001]
  • [Cites] Nat Rev Endocrinol. 2009 Jul;5(7):382-93 [19488074.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Jul;6(7):429-33 [19561636.001]
  • [Cites] Neuroendocrinology. 2009;90(1):67-72 [19521065.001]
  • [Cites] Cancer. 2009 Aug 1;115(15):3392-9 [19472402.001]
  • [Cites] Aliment Pharmacol Ther. 2009 Oct;30(7):733-40 [19573169.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4635-6 [19704053.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4656-63 [19704057.001]
  • [Cites] Endocr Relat Cancer. 2009 Dec;16(4):1351-61 [19726540.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):69-76 [19933912.001]
  • [Cites] Am J Clin Oncol. 2008 Jun;31(3):271-9 [18525307.001]
  • [Cites] Digestion. 2000;62 Suppl 1:79-83 [10940692.001]
  • [Cites] Ann Oncol. 2000 Sep;11(9):1127-30 [11061606.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3276-81 [11095353.001]
  • [Cites] J Surg Res. 2001 Jan;95(1):8-12 [11120628.001]
  • [Cites] Eur J Cancer. 2001 May;37(8):1014-9 [11334727.001]
  • [Cites] Cancer Control. 2001 Sep-Oct;8(5):454-60 [11579342.001]
  • [Cites] Surgery. 2001 Oct;130(4):677-82; discussion 682-5 [11602899.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):331-43 [11900219.001]
  • [Cites] Eur J Endocrinol. 2002 May;146(5):707-16 [11980628.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):614-21 [12056713.001]
  • [Cites] Expert Opin Pharmacother. 2002 Jun;3(6):643-56 [12472080.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):136-40 [12541121.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Radiology. 1993 Nov;189(2):541-7 [7692465.001]
  • [Cites] Endocrinol Metab Clin North Am. 1993 Dec;22(4):941-52 [8125079.001]
  • [Cites] Surgery. 1994 Dec;116(6):1111-6; discussion 1116-7 [7985095.001]
  • [Cites] Digestion. 1994;55 Suppl 3:92-7 [7698544.001]
  • [Cites] Am J Surg. 1995 May;169(5):523-8 [7747834.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):402-8 [8625251.001]
  • [Cites] Gut. 1996 Mar;38(3):430-8 [8675099.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):813-29 [9024720.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):1041-4 [9402179.001]
  • [Cites] Surgery. 1997 Dec;122(6):1147-54; discussion 1154-5 [9426432.001]
  • [Cites] Am J Surg. 1998 May;175(5):408-12 [9600289.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):372-8 [9669822.001]
  • [Cites] Transplantation. 1998 Nov 27;66(10):1307-12 [9846513.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):858-68 [10080850.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1381-7 [10235222.001]
  • [Cites] Acta Oncol. 2004;43(7):617-25 [15545182.001]
  • [Cites] Acta Oncol. 2004;43(7):626-36 [15545183.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2754-62 [15837990.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Gut. 2005 Jun;54 Suppl 4:iv1-16 [15888809.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1083-92 [16322345.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):401-6 [16421420.001]
  • [Cites] J Interferon Cytokine Res. 2006 Jan;26(1):8-13 [16426143.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):461-6 [16364959.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):21-7 [16625841.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):671-88 [16883305.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1148-54 [17031397.001]
  • [Cites] Eur J Endocrinol. 2006 Dec;155(6):849-57 [17132755.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S91-2S97 [17151568.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Feb;16(2):219-24 [17243941.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Apr;59(5):637-42 [16937105.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2986-91 [17505000.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5609-15 [18065733.001]
  • [Cites] Neuroendocrinology. 2008;87(1):8-19 [18097129.001]
  • [Cites] Neuroendocrinology. 2008;87(1):47-62 [18097131.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1316-23 [18323556.001]
  • [Cites] Ann Surg. 2008 Apr;247(4):659-65 [18362629.001]
  • [Cites] J Vasc Interv Radiol. 2008 Jun;19(6):855-61 [18503899.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3403-10 [18612155.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4311-8 [18779618.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):1005-15 [12637610.001]
  • [Cites] Br J Surg. 2003 Jun;90(6):687-93 [12808615.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):29-37 [12831921.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2689-96 [12860945.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):489-96 [14713263.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):966-73 [15151956.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2724-9 [15226340.001]
  • (PMID = 20380000.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 101
  • [Other-IDs] NLM/ PMC2852816
  •  go-up   go-down


6. Hillenbrand A, Sträter J, Henne-Bruns D: Frequency, symptoms and outcome of intestinal metastases of bronchopulmonary cancer. Case report and review of the literature. Int Semin Surg Oncol; 2005 Jun 6;2:13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency, symptoms and outcome of intestinal metastases of bronchopulmonary cancer. Case report and review of the literature.
  • BACKGROUND: We report a new case of small bowel metastases from primary lung cancer.
  • CASE PRESENTATION: The case involved a 56-year-old man with a squamous cell carcinoma of the lung (stage IV) that had been treated with chemotherapy.
  • Postoperative pathologic analysis confirmed the diagnosis of metastatic pulmonary carcinoma.
  • Most cases presented with bowel perforation or obstruction.
  • Squamous cell carcinoma was the most common histological cell type followed by large cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 1961 May;49:687-9 [13772590.001]
  • [Cites] Rev Pneumol Clin. 2003 Jun;59(3):161-5 [13130203.001]
  • [Cites] Mt Sinai J Med. 2003 Mar;70(2):130-2 [12634905.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Surg Today. 2001;31(4):358-62 [11321350.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):227-8 [10623713.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1884-7 [10406253.001]
  • [Cites] Acta Chir Belg. 1992 Jul-Aug;92(4):187-90 [1414135.001]
  • [Cites] J Surg Oncol. 1992 Dec;51(4):287-91 [1434663.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2003 Aug;41(8):537-40 [14503339.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2003 Dec;13(6):397-400 [14733704.001]
  • [Cites] Am Surg. 1992 Nov;58(11):677-82 [1485699.001]
  • [Cites] Kyobu Geka. 1991 Jul;44(7):596-9 [1886324.001]
  • [Cites] Arch Surg. 1990 May;125(5):583-5 [2158777.001]
  • [Cites] Can J Surg. 1979 Jul;22(4):351-3 [222418.001]
  • [Cites] Conn Med. 1989 Aug;53(8):455-6 [2670420.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1486-9 [3028602.001]
  • [Cites] Mil Med. 1988 Jan;153(1):30-2 [3126420.001]
  • [Cites] J Clin Gastroenterol. 1987 Oct;9(5):563-7 [3680909.001]
  • [Cites] Postgrad Med J. 1985 Feb;61(712):163-5 [3983047.001]
  • [Cites] J Can Assoc Radiol. 1974 Sep;25(3):242-4 [4424984.001]
  • [Cites] Cancer. 1972 Sep;30(3):806-9 [5075363.001]
  • [Cites] Am J Gastroenterol. 1969 Feb;51(2):145-50 [5776147.001]
  • [Cites] Am J Gastroenterol. 1980 Dec;74(6):504-6 [6259933.001]
  • [Cites] Acta Gastroenterol Belg. 1996 Jul-Sep;59(3):217-9 [9015935.001]
  • [Cites] J Chir (Paris). 1996 Sep;133(6):290-3 [8949275.001]
  • [Cites] Cancer. 1977 Jul;40(1):410-5 [880569.001]
  • [Cites] Kyobu Geka. 1995 Feb;48(2):169-71 [7897891.001]
  • [Cites] Acta Chir Belg. 2001 Nov-Dec;101(6):300-3 [11868507.001]
  • [Cites] Ann Surg. 1981 Jan;193(1):67-9 [7458451.001]
  • [Cites] Clin Oncol. 1980 Jun;6(2):181-6 [7408284.001]
  • [Cites] J Surg Oncol. 1983 Jun;23(2):93-4 [6855247.001]
  • [Cites] Ann Surg. 1983 Jan;197(1):120 [6848049.001]
  • [Cites] Endoscopy. 1994 Nov;26(9):752-3 [7712974.001]
  • (PMID = 15938753.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1180466
  •  go-up   go-down


7. Lau CP, Leung WK: Caecal metastasis from a primary small-cell lung carcinoma. Hong Kong Med J; 2008 Apr;14(2):152-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caecal metastasis from a primary small-cell lung carcinoma.
  • Small bowel metastases from a primary lung carcinoma are rare.
  • We report a case of a 59-year-old male with a primary small-cell lung carcinoma who developed anaemia and bowel symptoms.
  • On colonoscopic examination he was found to have a tumour in the caecum near the ileocaecal valve, which was biopsied, revealing small neuroendocrine tumour cells.
  • The patient then underwent systemic chemotherapy, which achieved a reduction in the size of the primary lung tumour and an improvement in his bowel symptoms.
  • It is important that such a rare condition be recognised early as complicated intestinal metastases from a lung carcinoma can lead to high mortality rates and poor short-term outcome.
  • With advances in chemotherapy and palliative care, patients with metastatic lung carcinoma can sometimes survive more than a year with reasonable quality of life.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382025.001).
  • [ISSN] 1024-2708
  • [Journal-full-title] Hong Kong medical journal = Xianggang yi xue za zhi
  • [ISO-abbreviation] Hong Kong Med J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


8. Clemente G, Chiarla C, Giovannini I, De Rose AM, Astone A, Barone C, Nuzzo G: Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer. Curr Med Res Opin; 2010 Mar;26(3):707-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer.
  • OBJECTIVES: Acute abdominal symptoms with CT scan evidence of intramural gas in bowel walls (pneumatosis cystoides intestinalis, PCI) and of gas in the portal venous blood (PBG) in patients undergoing chemotherapy may represent a worrisome picture, suggestive of bowel necrosis.
  • We describe a patient with acute abdominal symptoms and evidence of PCI with PBG under cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy for metastatic adenocarcinoma of the rectosigmoid junction.
  • METHODS: After admission for mucositis with diarrhea and profound dehydration, and subsequent emergency laparotomy for derotation of an intestinal volvulus, on the tenth postoperative day the patient developed fever and abdominal pain, with CT scan evidence of PCI with PBG.
  • The exam of the abdomen did not suggest major problems requiring emergency surgery, and antibiotic treatment with close monitoring were performed, followed by rapid improvement.
  • RESULTS: Twelve days later, after resumption of oral diet, the patient unexpectedly suffered a spontaneous jejunal microperforation, requiring emergency laparotomy and bowel resection.
  • Pathology showed that the perforation was within an area of ulceration involving the inner superficial layer of the bowel.
  • Subsequently recovery was normal and at present, after 15 months, the patient is well and continuing chemotherapy.
  • CONCLUSIONS: This is probably the first report of PCI with PBG related to intestinal toxicity during cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy in a patient with advanced rectal carcinoma, followed by delayed small bowel perforation.
  • It provides an example of the challenges involved in the management of this type of patient.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Gases. Pneumatosis Cystoides Intestinalis. Portal Vein / pathology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Cetuximab. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Rectal Neoplasms / drug therapy. Rectal Neoplasms / pathology. Tegafur / administration & dosage. Tegafur / adverse effects

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078321.001).
  • [ISSN] 1473-4877
  • [Journal-full-title] Current medical research and opinion
  • [ISO-abbreviation] Curr Med Res Opin
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Gases; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 1548R74NSZ / Tegafur; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin
  •  go-up   go-down


9. Douillard JY, Eckardt J, Scagliotti GV: Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer; 2002 Dec;38 Suppl 4:21-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging the platinum combinations in the chemotherapy of NSCLC.
  • In previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) the combination of docetaxel and gemcitabine is active and well tolerated.
  • A randomized phase III trial has shown that the combination of docetaxel and gemcitabine is as active as docetaxel plus cisplatin, achieving a 1-year survival rate of 39%, with significantly less neutropenia and gastro-intestinal toxicity.
  • All three docetaxel combinations (gemcitabine, vinorelbine, and irinotecan) could provide a valuable alternative to platinum-based chemotherapy and should be further evaluated in phase III setting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Paclitaxel / analogs & derivatives. Taxoids

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Elsevier Science Ireland Ltd.
  • (PMID = 12480191.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 53
  •  go-up   go-down


10. Lerouge D, Touboul E, Lefranc JP, Uzan S, Jannet D, Moureau-Zabotto L, Genestie C, Antoine M, Jamali M: [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion]. Cancer Radiother; 2004 Jun;8(3):168-77
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
  • [Transliterated title] Association concomitante préopératoire de radiothérapie et de chimiothérapie dans les cancers du col utérin opérables de stades IB2, IIA et IIB proximal de gros volume.
  • All patients underwent preoperative external beam pelvic radiation therapy (EBPRT) and concomitant chemotherapy during the first and the fourth radiation weeks combining 5-fluorouracil and cisplatin.
  • The pelvic dose was 40.50 Gy over 4.5 weeks.
  • EBPRT was followed by low-dose-rate uterovaginal brachytherapy with a total dose of 20 Gy in 17 pts.
  • Twenty-one of 25 pts who had not received preoperative uterovaginal brachytherapy underwent postoperative low-dose-rate vaginal brachytherapy of 20 Gy.
  • The 5-year local control rate and metastatic failure rate were 90% and 83.5%, respectively.
  • However, six pts had grade 3 acute intestinal toxicity.
  • Four severe late complications requiring surgical intervention were observed (one small bowel complication, three ureteral complications).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Carcinoma / radiotherapy. Neoplasm Invasiveness. Neoplasm Staging. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Brachytherapy. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoadjuvant Therapy. Radiation Injuries. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217584.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


11. Gücer F, Oz-Puyan F, Yilmaz O, Mülayim N, Balkanli-Kaplan P, Yüce MA: Endometrial carcinoma with laparotomy wound recurrence: complete remission following surgery and chemotherapy consisting of paclitaxel and carboplatin. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1195-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma with laparotomy wound recurrence: complete remission following surgery and chemotherapy consisting of paclitaxel and carboplatin.
  • We present a patient with surgical stage I endometrial cancer who experienced laparotomy wound recurrence 4 years after primary treatment.
  • She was treated successfully by complete surgical resection of recurrent tumors and chemotherapy.
  • A 62-year-old white female with laparotomy wound recurrence of endometrial carcinoma with small-bowel involvement and concomitant subcutaneous metastasis in the abdominal wall underwent complete surgical resection of metastatic tumors followed by six cycles of chemotherapy consisting of paclitaxel (175 mg/m2) and carboplatin (area under the curve 5).
  • Endometrial carcinoma with laparotomy wound recurrences, especially those with concomitant metastases, can be successfully treated by complete surgical resection followed by chemotherapy consisting of paclitaxel and carboplatin.
  • [MeSH-major] Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / therapy. Intestinal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carboplatin / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Paclitaxel / administration & dosage. Remission Induction. Surgical Procedures, Operative. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343212.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Ruoppolo M, Pezzica E, Milesi R, Corti D, Mercurio P, Fragapane G: [Neuroendocrine small-cell bladder cancer: our experience]. Urologia; 2010 Oct-Dec;77 Suppl 17:64-71
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine small-cell bladder cancer: our experience].
  • [Transliterated title] Carcinoma neuroendocrino a piccole cellule della vescica; nostra esperienza.
  • INTRODUCTION: Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.35-0.70% of all bladder tumors.
  • The small-cell carcinoma represents the most frequent histologic variant described.
  • Small-cell carcinoma is an epithelial tumor associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinoma.
  • At the time of presentation 59% of patients have clinical stage >T2 and 56% show metastatic disease.
  • PATIENTS AND METHODS: We report three cases of pure neuroendocrine small-cell bladder cancer.
  • Local advanced disease was present in all the cases with stage >T2, metastatic disease in 1 case, lymph node involvement and ureteral bilateral obstruction in 2.
  • Platinum-based adjuvant chemotherapy was proposed but only two patients received the treatment.
  • RESULTS: In 2 patients residual or relapsed cancer reappered within 2 months after surgery.
  • All of the three patients died of metastatic disease at 5, 7, and 13 months.
  • The most common site of relapse and spread of disease was the peritoneum and intestinal tract, and the reason of death was uncontrolled acute hemorrhage from gastro-intestinal district.
  • CONCLUSIONS: In the absence of a prospective study, and because of the rarity of the disease, the best treatment for small-cell bladder cancer remains uncertain.
  • Neoadjuvant chemotherapy with platinum regimen plus aggressive surgical approach will be the treatment of choice.
  • The association of chemotherapy and radiotherapy should also be considered.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Fatal Outcome. Gastrointestinal Hemorrhage / etiology. Hematuria / etiology. Humans. Intestinal Neoplasms / complications. Intestinal Neoplasms / secondary. Leukemia, Lymphocytic, Chronic, B-Cell. Liver Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasms, Second Primary. Peritoneal Neoplasms / secondary. Prostatic Neoplasms. Stomach Neoplasms. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308678.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Pratz KW, Ma C, Aubry MC, Vrtiska TJ, Erlichman C: Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome. Mayo Clin Proc; 2005 Jan;80(1):116-20
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome.
  • Verner-Morrison syndrome, characterized by diarrhea, hypokalemia, and hypochlorhydria, is caused most commonly by vasoactive intestinal polypeptide-secreting islet cell tumors of the pancreas.
  • Verner-Morrison syndrome has not been described as a paraneoplastic syndrome in non-small cell lung cancer.
  • We describe a 38-year-old man with metastatic non-small cell lung cancer of large cell carcinoma with neuroendocrine differentiation who presented with bone metastasis and intractable secretory diarrhea that was unresponsive to pharmacological treatment, including octreotide.
  • Laboratory evaluation indicated elevated serum calcitonin and vasoactive intestinal polypeptide levels.
  • Chemotherapy resulted in a transient response in the patient's diarrhea and neuroendocrine markers.
  • The patient did not respond to further therapy and died 5 months after onset of back pain.
  • To our knowledge, this is the first published case of large cell carcinoma with neuroendocrine differentiation associated with treatment-responsive paraneoplastic Verner-Morrison syndrome.
  • [MeSH-major] Calcitonin / secretion. Carcinoma, Large Cell / secretion. Lung Neoplasms / secretion. Pancreatic Neoplasms / etiology. Paraneoplastic Endocrine Syndromes / etiology. Vasoactive Intestinal Peptide / metabolism. Vipoma / etiology
  • [MeSH-minor] Adult. Humans. Male. Octreotide / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667039.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 37221-79-7 / Vasoactive Intestinal Peptide; 9007-12-9 / Calcitonin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


14. Scabini S, Rimini E, Romairone E, Scordamaglia R, Boggio M, Musizzano Y, Ferrando V: Small bowel metastasis from primary neuroendocrine small cell lung carcinoma. Chir Ital; 2009 Sep-Dec;61(5-6):679-82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel metastasis from primary neuroendocrine small cell lung carcinoma.
  • Small bowel metastases from a primary lung carcinoma are rare.
  • We report a case of a 76-year-old male with a primary neuroendocrine small cell carcinoma of the lung, treated by chemotherapy, who developed fever and bowel symptoms (subocclusion and pain).
  • On CT examination, he was found to have a tumour in the small bowel.
  • At operation we found small bowel occlusion by neoplasia and we therefore resected 15 cm of ileum with a side-to-side anastomosis.
  • Early recognition of this rare condition is important due to the fact that complicated intestinal metastases from lung carcinoma can lead to high mortality rates and poor short-term outcomes.
  • With advances in chemotherapy and palliative care, patients with metastatic lung carcinoma can sometimes survive more than a year with a reasonable quality of life.
  • [MeSH-major] Carcinoma, Neuroendocrine / secondary. Carcinoma, Neuroendocrine / surgery. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Ileal Neoplasms / secondary. Ileal Neoplasms / surgery. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Anastomosis, Surgical. Humans. Laparotomy. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380277.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Ortega J, Hayes JM, Antonia S: Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature. Cancer Chemother Pharmacol; 2009 Dec;65(1):187-90
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature.
  • It is most commonly caused by bowel necrosis and typically carries a grave prognosis.
  • Bevacizumab has emerged as an effective standard therapy in the frontline management of advanced non-small cell lung cancer (NSCLC).
  • CASE: A 75-year-old man, diagnosed with metastatic NSCLC, was treated with palliative chemotherapy consisting of paclitaxel, carboplatin, and bevacizumab for six cycles.
  • CONCLUSION: This is the first case of HPVG associated with bevacizumab therapy in a patient with metastatic NSCLC.
  • The HPVG may have been an early warning sign of impending bowel perforation, and bevacizumab was immediately discontinued, with HPVG completely resolving on follow-up CT scan 2 weeks later.
  • We recommend that bevacizumab therapy be immediately and permanently discontinued whenever HPVG is observed, as this may help avoid a potentially catastrophic outcome.
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Follow-Up Studies. Humans. Intestinal Perforation / chemically induced. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697030.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K24 CA128953
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


16. Okubo K, Yoshioka S, Asukai K, Hata T, Nakanishi M, Maekawa T, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Yano K, Fujimoto T: [A case report of primary adenocarcinoma of small intestine]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2792-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of primary adenocarcinoma of small intestine].
  • This is an account of a case of primary adenocarcinoma of the small intestine with peritoneal dissemination successfully treated with chemotherapy.
  • Abdominal computerized tomography revealed a bowel obstruction with tumor and the remarkable small bowel dilation of oral side of tumor.
  • Peritoneal dissemination was recognized around the ileocecal region, so ileum partial resection was performed for the primary cancer lesion and dissemination region.
  • The peritoneal dissemination consisted of metastatic adenocarcinoma from small intestine.
  • After an operation, internal use of S-1 was performed as adjuvant chemotherapy.
  • For lung metastasis, the combination chemotherapy with mFOLFOX6 + bevacizumab was administered.
  • Primary small intestinal adenocarcinoma is a rare disease, and it is often diagnosed as advanced cancer because of few characteristic symptoms.
  • So carcinoma of the small intestine usually has a poor prognosis.
  • [MeSH-major] Adenocarcinoma / therapy. Intestinal Neoplasms / therapy
  • [MeSH-minor] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bevacizumab. Combined Modality Therapy. Drug Combinations. Female. Fluorouracil / administration & dosage. Humans. Ileal Neoplasms / drug therapy. Leucovorin / administration & dosage. Lymphatic Metastasis. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / secondary. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224715.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 2S9ZZM9Q9V / Bevacizumab; 5VT6420TIG / Oxonic Acid; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


17. Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U: Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Invest New Drugs; 2009 Apr;27(2):184-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowel perforation in non-small cell lung cancer after bevacizumab therapy.
  • BACKGROUND: Bevacizumab is increasingly used in combination with chemotherapy for treatment of unresectable non-small cell lung cancer.
  • The aim of this report is to underline possible risks associated with this otherwise well-tolerated drug.
  • PATIENT: A 69-year-old patient with metastatic non-small cell lung cancer was started on a palliative chemotherapy regimen containing carboplatin, paclitaxel, and bevacizumab.
  • RESULTS: After the second cycle of chemotherapy, the patient developed abdominal pain.
  • On emergency laparotomy, there was diffuse perforation of the colonic wall, so the patient underwent a Hartmann's procedure with subtotal colectomy.
  • CONCLUSION: Gastrointestinal perforation is a known adverse event of bevacizumab therapy which so far has occurred only in patients with predisposing risk factors.
  • Our patient illustrates that there must always remain a high index of suspicion regarding bowel perforation in patients developing acute abdominal pain under bevacizumab therapy, even if they have no apparent risk factors.
  • [MeSH-major] Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal / adverse effects. Carcinoma, Non-Small-Cell Lung / complications. Intestinal Perforation / chemically induced. Lung Neoplasms / complications
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Humans. Male. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):118-23 [17658587.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):3-6 [17383545.001]
  • [Cites] Oncologist. 2007 Jun;12(6):713-8 [17602060.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):1011-27 [15585754.001]
  • [Cites] BMC Cancer. 2007 May 30;7:91 [17537235.001]
  • [Cites] J Thorac Oncol. 2007 Jun;2(6):571-3 [17545855.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2729-35 [17363594.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Clin Ther. 2006 Nov;28(11):1779-802 [17212999.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1295-8 [16503384.001]
  • [Cites] J Med Case Rep. 2008 Feb 13;2:47 [18271967.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):83-9 [16736514.001]
  • [Cites] Chirurg. 2008 Apr;79(4):351-5 [17453167.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):1961-70 [17404076.001]
  • [Cites] J Surg Oncol. 2008 Feb 1;97(2):180-5 [18095268.001]
  • (PMID = 18665327.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Frampton JE, Easthope SE: Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. Drugs; 2004;64(21):2475-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.
  • Gefitinib (Iressa), the first commercially available epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC).
  • Japan and Australia) and, additionally, in patients considered unsuitable for chemotherapy (e.g.
  • Few third-line treatment options exist for patients with inoperable advanced NSCLC who have failed both platinum-based and docetaxel chemotherapies.
  • Gefitinib represents a significant advance in the treatment of this population; a once-daily, oral dosage of 250 mg/day was well tolerated, produced objective tumour responses and disease stabilisation, and improved disease-related symptoms and quality of life.
  • It also produced overall survival outcomes that compared favourably with historical outcomes in a similar group of patients treated with three or four different chemotherapy regimens.
  • Ongoing or planned clinical trials are designed to confirm and/or further define the role of the drug in the above and other clinical settings.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / drug effects
  • [MeSH-minor] Aged. Biological Availability. Half-Life. Humans. Intestinal Absorption. Metabolic Clearance Rate. Middle Aged. Quality of Life. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Health Syst Pharm. 2004 May 1;61(9):889-98 [15156965.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):32S-40S [11560969.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2240-50 [11980995.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):33-7 [14679116.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6629-38 [14528288.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1103-9 [15020612.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5813-24 [14676101.001]
  • [Cites] Lung Cancer. 2004 Mar;43(3):317-22 [15165090.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):39-48 [12644983.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):418-24 [15238978.001]
  • [Cites] Adv Exp Med Biol. 2003;532:247-52 [12908563.001]
  • [Cites] Eye (Lond). 2005 Jul;19(7):729-38 [15688060.001]
  • [Cites] JAMA. 2004 Jul 28;292(4):470-84 [15280345.001]
  • [Cites] JAMA. 2004 Jul 28;292(4):499-500 [15280349.001]
  • [Cites] Lung Cancer. 2003 Jan;39(1):55-61 [12499095.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4607-13 [15269131.001]
  • [Cites] Ann Pharmacother. 2003 Nov;37(11):1644-53 [14565788.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]
  • [Cites] Br J Cancer. 2003 Dec;89 Suppl 2:S9-14 [14661047.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):759-61 [14990627.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):82-6 [14710211.001]
  • [Cites] J Clin Pharm Ther. 2004 Apr;29(2):95-103 [15068398.001]
  • [Cites] Oncology (Williston Park). 2003 Jul;17(7):957-63; discussion 963, 968-70 [12886865.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Lung Cancer. 2004 Aug;45(2):221-5 [15246194.001]
  • [Cites] Clin Lung Cancer. 2004 Apr;5 Suppl 2:S75-9 [15117429.001]
  • [Cites] Drugs. 2002;62(15):2237-48; discussion 2249-50 [12381224.001]
  • [Cites] Expert Opin Emerg Drugs. 2003 May;8(1):179-92 [14610920.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 1):93-9 [14981586.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Ann Oncol. 2004 May;15(5):786-92 [15111348.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1827-9 [14612886.001]
  • [Cites] Am J Health Syst Pharm. 2002 Apr 1;59(7):611-42 [11944603.001]
  • [Cites] Drugs. 2000;60 Suppl 1:33-40; discussion 41-2 [11129170.001]
  • [Cites] Clin Lung Cancer. 2003 May;4(6):366-9 [14599302.001]
  • [Cites] Br J Cancer. 2003 Dec;89 Suppl 2:S19-23 [14661049.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):49-55 [12644984.001]
  • [Cites] Oncologist. 2003;8(4):303-6 [12897327.001]
  • [Cites] Oncology (Williston Park). 2002 Jun;16(6 Suppl 6):45-51 [12108897.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):566-72 [14760365.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41 [15292385.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 4;96(15):1117-9 [15292378.001]
  • (PMID = 15482004.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Number-of-references] 88
  •  go-up   go-down


19. Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, Wagener T, Anak O, Baron B, Nordlinger B, EORTC Gastro Intestinal Tract Cancer Group: A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer; 2005 Feb;41(3):398-403
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
  • Previous small phase II trials have demonstrated that the combination of 5-fluorouracil (5FU) and cisplatin(CDDP) could have clinical activity in metastatic biliary tract cancer.
  • Patients were included if they had histologically proven locally advanced or metastatic biliary tract carcinoma, World Health Organisation (WHO) performance status < or = 2, bilirubin <2 x upper normal limit, adequate haematological and renal functions and had not received prior chemotherapy, even in the adjuvant setting.
  • TREATMENTS: Arm A (HDFU) consisted of cycles of 5FU 3 g/m(2) intravenously (i.v.
  • In both arms, the most common metastatic sites were the liver and peritoneum.
  • Twenty-eight patients were eligible in each arm and one patient did not start the allocated therapy in Arm B.
  • Responses for the eligible patients who started their allocated therapy were as follows: Complete Response (CR) 0% in Arm A, 4% in Arm B, Partial Response (PR) 7% in Arm A, 15% in Arm B resulting in an overall response rate [95% CI] of 7.1% in Arm A [0.9-23.5%] and 19% [6.3-38.1%] in Arm B.
  • National Cancer Institute of Canada (NCIC) grade 3-4 adverse events (% of patients in Arm A/Arm B) were neutropenia 4%/26%, thrombopenia 0%/7%, stomatitis 0%/4%, vomiting 7%/14%, diarrhoea 0%/11% and neurotoxicity 4%/0%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Disease Progression. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Risk Factors. Survival Analysis. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691639.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Schöffski P, Bukowski R, Flodgren P, Ravaud A: Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. Ann Oncol; 2009 May;20 Suppl 1:i25-i30
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports.
  • BACKGROUND: Sunitinib malate is approved multinationally for the treatment of metastatic renal cell carcinoma (mRCC) and advanced imatinib-refractory gastrointestinal stromal tumour (GIST).
  • DESIGN: This report describes four patient cases in which sunitinib was utilised for the management of advanced malignancies: two cases describe mRCC patients who received first-line sunitinib and two cases describe the use of targeted therapies, including sunitinib, in patients with advanced GIST.
  • RESULTS: In all four cases, effective AE management enabled patients to receive long-term therapy with sunitinib and achieve sustained clinical benefit.

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430005.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


21. Gray J, Murren J, Sharma A, Kelley S, Detterbeck F, Bepler G: Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab. J Thorac Oncol; 2007 Jun;2(6):571-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
  • Bowel metastasis and perforation in patients with non-small cell lung cancer is rare.
  • Bevacizumab has emerged as a new therapy in the treatment of metastatic non-small cell lung cancer.
  • Bowel perforation associated with its use has been described in colon and ovarian cancers.
  • In this report, we present the first known case of visceral perforation in a patient with metastatic non-small cell lung cancer after treatment with bevacizumab.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Gastrointestinal Neoplasms / drug therapy. Intestinal Perforation / etiology. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545855.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


22. Regine WF, Hanna N, Garofalo MC, Doyle A, Arnold S, Kataria R, Sims J, Tan M, Mohiuddin M: Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm. Int J Radiat Oncol Biol Phys; 2007 May 1;68(1):172-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm.
  • PURPOSE: To determine the maximum tolerated dose of upper abdominal low-dose fractionated radiotherapy (<1.0 Gy per fraction) given in combination with, and as a chemopotentiator for, gemcitabine.
  • Ten patients have been entered in Phase I: 6 with metastatic/recurrent pancreatic carcinoma and 4 with unresectable pancreatic/small bowel carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Dose Fractionation. Drug Administration Schedule. Female. Humans. Intestine, Small. Male. Middle Aged. Radiation-Sensitizing Agents / adverse effects. Radiation-Sensitizing Agents / therapeutic use

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276612.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


23. Dominguez PA, Dervisis NG, Cadile CD, Sarbu L, Kitchell BE: Combined gemcitabine and carboplatin therapy for carcinomas in dogs. J Vet Intern Med; 2009 Jan-Feb;23(1):130-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined gemcitabine and carboplatin therapy for carcinomas in dogs.
  • BACKGROUND: Response and adverse reactions to combined gemcitabine (GEM) and carboplatin (CARBO) therapy in dogs with carcinomas are not documented.
  • HYPOTHESIS: GEM and CARBO are safe for the treatment of dogs with carcinomas.
  • Twelve dogs (32%) developed neutropenia (3 Grade 3, and 5 Grade 4) and 9 (24%) thrombocytopenia (2 Grade 3, and 1 Grade 4).
  • One dog died of treatment-related complications.
  • One dog with metastatic prostatic carcinoma achieved a complete remission and 1 dog with intestinal adenocarcinoma and 1 with tonsillar squamous cell carcinoma achieved partial remission.
  • CONCLUSION AND CLINICAL IMPORTANCE: GEM and CARBO combination causes mild to moderate hematologic and GI toxicosis in dogs with carcinoma.

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175731.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down






Advertisement